Related Experiment Video
Updated: Oct 8, 2025
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude
Hui Shen1, Dan Wang1, Mengyun Zhan1
1Department of Dermatology, Taikang Tongji (Wuhan) Hospital, Wuhan, China.
Background:
MicroRNA (miR)-146a and miR-146b regulate autoimmunity, inflammation, and keratinocytes proliferation to engage in psoriasis pathology. The current study aimed to investigate their correlation with disease risk and clinical features, and the linkage of their longitudinal changes with clinical response to etanercept in psoriasis patients.
Methods:
Plasma samples were collected from 84 moderate-to-severe psoriasis patients who underwent etanercept treatment (at baseline (M0), 1 month (M1), 3 months (M3), and 6 months (M6)), 80 disease controls and 80 health controls (both after enrollment); afterward, miR-146a and miR-146b expressions were detected by RT-qPCR. Furthermore, PASI75 and PASI90 responses were assessed in psoriasis patients.
Results:
Both miR-146a and miR-146b were decreased in psoriasis patients compared with disease controls and health controls (all p < 0.001), which also distinguished psoriasis patients from disease controls and health controls by receiver-operating characteristic analyses. Furthermore, miR-146a positively correlated with miR-146b in psoriasis patients (p < 0.001) and disease controls (p = 0.005) but not in healthy controls (p = 0.062). In psoriasis patients, miR-146a negatively related to psoriatic body surface area (p = 0.011) and PASI score (p = 0.003); miR-146b negatively linked with PASI score (p = 0.020). At M1, M3, and M6 after etanercept treatment, PASI75 response rate was 14.3%, 32.1%, and 69.0%, respectively; PASI90 response rate was 1.2%, 17.9%, and 36.9%, respectively. During etanercept treatment, both miR-146a and miR-146b elevated gradually over time and their longitude increments were associated with PASI75 response (all p < 0.001).
Conclusion:
MiR-146a and miR-146b might serve as indicators for optimizing etanercept application and improving treatment outcomes in psoriasis patients.
Insights
MicroRNA-146a and microRNA-146b levels are decreased in psoriasis patients. Their levels increase during etanercept treatment and correlate with improved treatment outcomes, suggesting they can help optimize therapy.
Area of Science:
- Dermatology
- Molecular Biology
- Immunology
Background:
- Psoriasis involves autoimmunity, inflammation, and keratinocyte proliferation, processes regulated by microRNA-146a (miR-146a) and microRNA-146b (miR-146b).
- Understanding the role of these microRNAs in psoriasis pathogenesis and their response to treatment is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the correlation of miR-146a and miR-146b with psoriasis risk and clinical features.
- To assess the linkage between longitudinal changes in miR-146a and miR-146b levels and clinical response to etanercept treatment in psoriasis patients.
Main Methods:
- Plasma samples were collected from 84 psoriasis patients undergoing etanercept treatment, 80 disease controls, and 80 healthy controls.
- miR-146a and miR-146b expressions were quantified using RT-qPCR at multiple time points during treatment.
- Psoriasis Area and Severity Index (PASI) scores were used to assess treatment response (PASI75 and PASI90).
Main Results:
- Both miR-146a and miR-146b were significantly decreased in psoriasis patients compared to controls (p < 0.001).
- miR-146a and miR-146b levels negatively correlated with psoriasis severity (body surface area and PASI score).
- During etanercept treatment, miR-146a and miR-146b levels gradually increased and were associated with achieving PASI75 response (p < 0.001).
Conclusions:
- miR-146a and miR-146b may serve as potential biomarkers for predicting treatment response in psoriasis.
- These microRNAs could aid in optimizing etanercept application and improving therapeutic outcomes for psoriasis patients.
Related Concept Videos
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:22MicroRNAs